Trial Profile
A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharma KK; Novartis Pharmaceuticals
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 18 Apr 2019 to 8 Apr 2019.